Trial intelligence / Profile preview

EGFR CART for Metastatic Colorectal Cancer

NCT03152435Phase 2Unknown

Sponsor
Shenzhen Second People's Hospital
Start
Jun 2017
Primary completion
Sep 2019
Modality
CAR-T Cells
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of EGFR CART in metastatic colorectal cancer (mCRC), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Occurrence of study related adverse events at 24 weeks. Status: unknown.

02

Drugs

EGFR CART
03

Conditions

metastatic colorectal cancer (mCRC)

Beyond the preview

Go deeper on NCT03152435.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03152435.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call